B A C K G R O U N D
Periodontal disease is a microbial infection involving a variety of microbes that trigger inflammation, loss of connective tissue attachment and alveolar bone around the teeth. The primary etiologic factor of periodontitis is bacterial plaque. The bacteria involved are mainly of gram-negative species, express pathogenic factors that elicit host defence responses resulting in inflammation and tissue destruction. In fact, the propensity of periodontitis to proceed with periods of exacerbation and remission could suggest that the presence of other organisms contributes in the disease progression. 1 The development of periodontitis may depend upon cooperative interactions among specific pathogenic bacteria and tissue destructive inflammatory mediators. Various evidences has shown relationship between type 2 diabetes and periodontal disease. 2 However, the effect of periodontal intervention on these elements is yet to be ascertained.
Diabetes is a group of metabolic diseases characterized by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycaemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the β-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycaemia.
At present, a bidirectional pathway has been suggested between DM and periodontitis, since patients with DM are more predisposed to periodontal diseases, the established periodontitis may simultaneously impair adequate glycaemic control. 3 Moreover, poorly controlled diabetic subjects, presenting elevated levels of glycosylated haemoglobin (HbA1c), show higher attachment and alveolar bone loss and local inflammatory cytokines than well controlled patients 3, 4 Exacerbated local inflammation in diabetic subjects with inadequate glycaemic control could modify the subgingival environment, and consequently, the subgingival microbial profile. Evidence has shown variations in the micro flora in non-diabetic and diabetic individuals; and also, within the diabetic individuals as well, based on their glycaemic control. 5, 6 We wanted to assess, compare and correlate the change in bacterial pathogen concentrations in plaque as confirmed polymerize chain reaction (PCR) in patients with and without type-2 diabetes before and after phase-1 therapy in patients with chronic periodontitis. 
ME T H O D S

Method of Collection of Data
In this study, which was of 4 months duration, following initial screening, 120 patients with chronic periodontitis (Mild to moderate) were divided into 2 main groups based on their glycaemic status. Glycated haemoglobin levels were assessed using standardized assay-High Pressure Liquid Chromatography (HPLC).
Group-1-Control (n=30)
30 non-diabetic patients with chronic periodontitis. 
Group
Treatment Procedure
Clinical Aspect-All the 120 patients were subjected to phase 1 therapy. After assessing the clinical parameters ultrasonic scaling was done followed by thorough root planing at baseline. Patients were recalled after 1 month and 4 months during which time, plaque samples were collected, and clinical parameters were recorded.
Microbiological Aspect-The plaque samples were subjected to PCR. The main components of the PCR Master Mix were HemoklenTaq buffer 5x, dNTP (2.5 mM), HaemoklenTaq enzyme and PCR water. Additives like DMSO, glycerol and formamide were also added for getting better results.
PCR Protocol
For PCR, bacterial DNA from the plaque samples was amplified in 50 µl of a reaction mixture containing 3 µl of the DNA sample, 1X PCR buffer (50 mMKCl, 1.5 mMMgClz, 10 mM Tris-HCl, pH 9.0), 2.5 mM deoxyribonucleotide mixture 1 µl of each primer, and 0.5-1 µl of haemoklenTaq DNA polymerase (NAB) in a thermal cycler for 30 cycles. After amplification, 20 µl of the PCR product was analyzed by agarose gel electrophoresis by incorporating propidium iodide on 1% gel. The newly synthesized DNA fragments were then visualized under ultraviolet light. The size of the PCR products was estimated from the electrophoretic migration of products relative to a 1 kb ladder marker. (Thermoscientific).
Statistical Analysis
All the clinical, microbiological and biochemical parameters recorded were statistically analysed using SPSS software version 13, and Paired t test. 
R E S U L T S
P. gingivalis (PG)-Intra Group (
P. gingivalis (PG)-Inter Group (
P. intermedia (PI)-Intra Group (Table 3A, Graph 3A)
Group-1 (control): The mean difference in P. intermedia counts between baseline and 1 month was 1755333333.33+ 3731564092.27, at baseline and 4 months was 1775000000.00+ 3750355155.60 and 1 month and 4 months was 19666666.67+ 37644739.82. This difference was found to be statistically significant (p˂0.05) at all time intervals i.e. from baseline to 1 month, baseline to 4 months & from 1 month to 4 months.
Group-2A (Test): The mean difference in P. intermedia counts between baseline and 1 month was 1821333333.33+ 3716936756.33, at baseline and 4 months was 1799666666.67+3652283634.53 and 1 month and 4 months was -21666666.67+ 310428883.90. This difference was found to be statistically significant (p˂0.05) at baseline to 1 month and baseline to 4 months but not from 1 month to 4 months, (p>0.05).
Group-2B (Test):
The mean difference in P. intermedia counts between baseline and 1 month was 2124666666.67+3927763014.60, at baseline and 4 months was 2169000000.00+3988301297.71 and 1 month and 4 months was 44333333.33+ 184216576.69. This difference was found to be statistically significant (p˂0.05) at baseline to 1 month, baseline to 4 months but not from 1 month to 4 months, (p>0.05).
Group-2C (Test):
The mean difference in P. intermedia counts between baseline and 1 month was 287266670.30+421938784.74, at baseline and 4 months was 292633336.97+501342091.10 and 1 month and 4 months was 5366666.67+370736404.49. This difference was found to be statistically significant (p ˂0.05) at baseline to 1 month, baseline to 4 months but not from 1 month to 4 months, (p>0.05).
P. intermedia (PI)-Inter Group (Table 3B, Graph 3B)
Inter group comparisons of Pi counts revealed no significant differences between all the four groups at the end of 1 month and 4 months respectively,(p>0.05). 
Groups
D I SC U S SI O N
Periodontitis usually results from the complex interactions of the microbial communities with the host elements in the gingival sulcus that leads to inflammation, loss of connective tissue attachment and alveolar bone around the teeth. 6 Diabetes mellitus (DM) is well recognized as a risk factor for periodontal disease, while periodontitis is thought to influence the systemic inflammatory condition, lipid and glucose metabolism and insulin resistance. 7 Diabetes mellitus, especially when uncontrolled, appears to be an important risk factor for periodontal destruction, since an alteration in host-response and microbiological aspects occurs in diabetic subjects. 8 Periodontal disease leads to an increase in insulin resistance, which could impair glycaemic control. Thus, the control of periodontal disease is necessary for better systemic health in these individuals. Periodontal treatment relies on biofilm disruption and plaque control to prevent recolonization and recurrence of the disease. 8 The relationship between plaque accumulation and HbA1c levels remains controversial. [9] [10] [11] Some reports have observed an improved compliance with oral hygiene amongst diabetic subjects with better glycaemic control, while others have not found this association. [12] [13] [14] Some studies have shown the impact of type 1 and type 2 DM on tooth loss, 15 but the association between metabolic control and the number of remaining teeth has not been considered. Previous studies have shown that the microbiota associated with diabetes does not appear different from the microbiota of non-diabetic patients. [15] [16] [17] [18] [19] Although the microbiology of periodontal disease in DM is fairly well understood. The sample size of 120 patients evaluated in this study was arrived at following consultation with the statistician which was in accordance with the vast majority of clinical periodontal treatment studies in humans. 20 In order to understand this phenomenon with better sensitivity and specificity, it was decided to carry out the study by dividing the 120 patients into 4 groups based on the level of glycaemic control.
The clinical parameters (GI, PI, PPD, RAL) were assessed to evaluate the disease severity at regular intervals and also to understand whether phase-1 therapy has an effect on patients with chronic periodontitis with and without diabetes.
The gold standard for recording changes in periodontal status is the longitudinal measurements with relative attachment level (RAL) from CEJ to the base of the pocket. Due to the relative inconsistencies in determining CEJ accurately at the selected sites, it was decided to use a customized acrylic stent and use the base of the stent as the fixed reference point and evaluate relative attachment level (RAL).
In addition, the microbiological analysis with the help of multiplex PCR technique was done to evaluate the effect of phase-1 therapy on bacterial concentrations in patients with chronic periodontitis with and without diabetes. Single-stage PCR was used to detect P. gingivalis, P. intermedia, and T. forsythia. It has been suggested that pooling of plaque samples increases the probability of detecting existing pathogens. 21 Intergroup comparison revealed, a significant improvement in glycated Hb levels in the non-diabetic group as compared to the diabetic groups at 1 month following phase-1 therapy. Additionally significant improvement was also observed in the well-controlled and moderately controlled diabetic group when compared with the poorly controlled group. This is in accordance with Taylor et al 2008, 22 Shlossman 1990 23 who concluded that phase-1 therapy improves the glycaemic status of diabetic patients with chronic periodontitis.
With regard to the microbiologic parameters, intra group comparison revealed a significant improvement in Pg counts, Tf count, Pi count, count with in both the test (Diabetic) and control (non-diabetic) group from baseline to 1 month and 4 months except in poorly controlled diabetic group at 1 month and 4 months. This is in accordance with the findings of Sandholm et al 1989 24 2008 26 who concluded that phase-1 therapy results in reduction of bacterial counts in patients with chronic periodontitis and diabetes and also with Hintao et al 2007 27, IbrahimuMdala 2013 28 who concluded that phase-1 therapy results in reduction of bacterial counts in patients with chronic periodontitis Inter group comparison revealed significant reduction in Pg counts, Tf count, Pi count, in the non-diabetic group compared to the poorly controlled diabetic group and well controlled diabetic group compared to poorly-controlled diabetic group at the end of 4 months. But interestingly no such differences were observed at 1 month. This is accordance with Makiura et al 2008 29 who concluded that Pg counts were reduced in the patients with diabetes following phase-1 therapy.
C O N C L U S I O N S
In-vitro microbiological assessment (PCR analysis) showed significant reduction of bacteria within both diabetic and non-diabetic groups. In contrast, the intergroup comparison revealed no significant difference in the microbial counts in both the diabetic and non-diabetic groups thus suggesting that phase-1 therapy may not alter the pathogenic microflora in chronic periodontitis patients with or without diabetes. Correlation assessments of clinical parameters with the microbiological and biochemical parameters showed significant correlation at various time intervals again suggesting that phase 1 therapy results in improved clinical and microbiologic status and glycaemic status in chronic periodontitis patients with and without diabetes.
